Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria.~* Subjects must have active RA disease as defined by:~  * At least 6 tender joints and 6 swollen joints~ * ESR of 28 mm/hour or CRP of 2.0 mg/dL~* Subjects who have failed to respond or have been resistant to at least one DMARD (including MTX)~* Subjects in whom MTX cannot be administered for any of the reasons(incomplete response/safety concerns)~Exclusion Criteria:~* Patients who have a diagnosis of any other inflammatory arthritis~* Patients who have a secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)~* Patients who currently have, or who have a history of, a demyelinating or convulsive disease of the central nervous system (eg, multiple sclerosis, epilepsy)~* Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure~* Patients who currently have, or who have a history of, tuberculosis~* Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)~* Patients who currently have, or who have a history of, malignancy~* Female patients who are breastfeeding or pregnant, who are of childbearing potential~* Patients who previously received treatment with 2 or more anti-TNFα drugs or who previously failed to respond to treatment with 1 or more aint-TNFα drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CDP870 200mg (Type: EXPERIMENTAL): 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of CDP870

Based on this trial design, predict the completion outcome and termination type (if applicable).